Acasti Pharma Inc  

(Public, CVE:ACST)   Watch this stock  
Find more results for CVE:APO
1.76
+0.09 (5.39%)
Dec 2 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.76 - 1.83
52 week 1.50 - 4.40
Open 1.83
Vol / Avg. 400.00/3,324.00
Mkt cap 16.66M
P/E     -
Div/yield     -
EPS -0.90
Shares 10.71M
Beta 1.34
Inst. own     -
Oct 11, 2016
Q2 2017 Acasti Pharma Inc Earnings Release
  

Key stats and ratios

Q3 (Aug '16) 2016
Net profit margin -63834.25% -16773.05%
Operating margin -67136.16% -25521.54%
EBITD margin - -18261.84%
Return on average assets -37.91% -19.22%
Return on average equity -40.51% -20.90%
Employees 11 -
CDP Score - -

Address

545 Prom du Centropolis Suite 100
LAVAL, QC H7T 0A3
Canada
+1-450-6864555 (Phone)
+1-450-6862505 (Fax)

Website links

Description

Acasti Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing, clinically studying and marketing new pharmaceutical products to treat human cardiovascular conditions. The Company is involved in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Company's prescription drug candidate is CaPre, which is being developed for the treatment of severe hypertriglyceridemia and eventually mild to moderate hypertriglyceridemia. The Company's ONEMIA has a natural health product status in Canada, and it is commercialized as a medical food in the United States. Onemia is a purified omega-3 phospholipids concentrate derived from krill oil with lower levels of phospholipids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) content than CaPre.

Officers and directors

Roderick Noel Carter Executive Chairman of the Board
Janelle D'Alvise President, Chief Executive Officer
Linda O'Keefe Chief Financial Officer
Pierre Lemieux Ph.D. Chief Operating Officer
Laurent Harvey Vice President- Clinical and Non-Clinical Affairs
Jean-Daniel Belanger Secretary, Director- Corporate Affairs
Valier Boivin Independent Director
Jean-Claude Debard Independent Director
Ronald Denis Independent Director
Pierre Fitzgibbon Independent Director
Age: 61